Hot Industrial Disributor Stocks To Watch For 2014

NEW YORK (MarketWatch) ��Will Twitter Inc. soar or tank after its stock-market debut?

Investors are looking for big moves from the social-media company�� stock after its initial public offering on the New York Stock Exchange Thursday.

Reuters Enlarge Image A sign displays the Twitter logo on the front of the New York Stock Exchange ahead of the company's IPO in New York.

Twitter (TWTR) ��priced its shares at $26 late Wednesday. Cantor Fitzgerald analysts have already assigned the stock a price target of $32. Follow our live-stream updates on the #TwitterIPO here.

Top 5 Construction Stocks To Invest In Right Now: Dividend and Income Fund (DNI)

Dividend and Income Fund (the Fund) is a closed end management investment company. The Fund focuses to invest, at least 50% of its total assets in equity securities, including dividend paying common stocks, convertible securities, preferred stocks, securities of registered and unregistered investment companies (including, but not limited to, closed end and open end management investment companies, and business development companies) (collectively, investment companies), exchange traded funds organized as investment companies or otherwise, real estate investment trusts, depositary receipts, and other equity related securities (collectively, Income Generating Equity Securities). The Fund may invest in fixed income securities, including bonds issued by domestic and foreign corporate entities and U.S. government securities. Bexil Advisers LLC acts as the Investment Manager of the Fund. Advisors' Opinion:

• [By Dividends4Life]

  According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer

Hot Industrial Disributor Stocks To Watch For 2014: SurModics Inc.(SRDX)

SurModics, Inc. provides drug delivery and surface modification technologies to the healthcare industry. The company offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, and urology markets. It also provides a range of drug delivery technologies for injectable therapeutics, including microparticles, nanoparticles, and implants addressing a range of clinical applications, such as ophthalmology, oncology, dermatology, and neurology. In addition, the company provides in vitro diagnostic component products and technologies comprising microarray slide technologies, protein stabilization reagents, substrates, polymers and reagent chemicals, and antigens for diagnostic test kits and biomedical research applications. SurModics, Inc. market s its technologies and products worldwide through direct sales force consisting of sales professionals. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SurModics (Nasdaq: SRDX  ) , whose recent revenue and earnings are plotted below.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SurModics (Nasdaq: SRDX  ) , whose recent revenue and earnings are plotted below.

Hot Industrial Disributor Stocks To Watch For 2014: Jabil Circuit Inc.(JBL)

Jabil Circuit, Inc., together with its subsidiaries, provides electronic manufacturing services and solutions worldwide. The company offers electronics and mechanical design, production, product management, and after-market services to companies in the aerospace, automotive, computing, consumer, defense, industrial, instrumentation, medical, networking, peripherals, solar, storage, and telecommunications industries. Its services comprise integrated design and engineering; component selection, sourcing, and procurement; automated assembly; design and implementation of product testing; parallel global production; enclosure services; and systems assembly, direct-order fulfillment, and configure-to-order services. The company also provides set-top boxes, mobility products, and display products, as well as peripheral products, such as printers and point of sale terminals; and aftermarket services consisting of warranty and repair services. Jabil Circuit, Inc. was founded in 196 6 and is headquartered in St. Petersburg, Florida.

Advisors' Opinion:

• [By Rich Bieglmeier]

  [Related -Jabil Circuit, Inc. (JBL) Analyst Day Preview: All Eyes On Blackberry Ltd (BBRY) Update]

  Jabil is a provider of worldwide electronic manufacturing services and solutions. Jabil provides electronics design, production and product management services to companies in the aerospace, automotive, computing, consumer, defense, industrial, instrumentation, medical, networking, peripherals, solar, storage and telecommunications industries. The Company operates in three segments: Diversified Manufacturing Services (DMS), Enterprise & Infrastructure (E&I) and High Velocity Systems (HVS).

• [By Reuters]

  Simon Dawson/Bloomberg via Getty Images TORONTO -- BlackBerry reported a quarterly loss of nearly $1 billion Friday, in line with last week's warning, days after accepting its largest shareholder's tentative $4.7 billion bid to take it out of the public eye. BlackBerry (BBRY), which had warned of poor results on Sept. 20, said its net loss for the second quarter ended on Aug. 31 was $965 million, or $1.84 a share. Revenue fell 45 percent to $1.6 billion from a year earlier. The loss included a writedown of about $934 million for unsold Z10 phones, a touchscreen model that the company had hoped would reverse its fading fortunes. The phone has sold badly with business and consumer customers alike. "This write-off is very real," said Morningstar (MORN) analyst Brian Colello. "They bought a lot of inventory hoping to sell it. The auditors were not convinced that BlackBerry can sell it or sell it at prices that the company was hoping for. We see no reason to be more optimistic than them." Excluding the Z10 writedown and restructuring costs, BlackBerry reported a loss of $248 million, or 47 cents a share. The company plans to shed 4,500 jobs, or more than one-third of its workforce, as it shrinks to focus on corporate and government customers. It will not host the typical post-results call for investors after signing a tentative $9-a-share agreement to be acquired by a consortium led by Fairfax Financial, its largest shareholder, Monday. The Waterloo, Ontario-based company's steep revenue decline and mounting losses have revived fears that BlackBerry, a pioneer in the smartphone sector, faces an ignominious death. "We are very disappointed with our operational and financial results this quarter and have announced a series of major changes to address the competitive hardware environment and our cost structure," Chief Executive Officer Thorsten Heins said in the earnings statement. BlackBerry said Heins wasn't available for an interview. The company said it

• [By Mani]

  Jabil Circuit, Inc. (NYSE: JBL) is holding its analyst day on�Oct. 30�in Boston followed by an afternoon event in Clinton where investors will get to see Nypro's facilities first hand.

Hot Industrial Disributor Stocks To Watch For 2014: Infinity Pharmaceuticals Inc.(INFI)

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for difficult-to-treat diseases. The company?s lead product candidates include saridegib (IPI-926), an oral molecule with the potential to treat a range of cancers by disrupting malignant activation of the Hedgehog pathway; and Retaspimycin HCl (IPI-504), a heat shock protein 90 (Hsp90) inhibitor. Its Saridegib is in a Phase II clinical trial for the treatment of metastatic or inoperable chondrosarcoma and a Phase II exploratory trial in patients with myelofibrosis. The company?s Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC); and in a Phase Ib/II trial in combination with everolimus, known as Afinitor, in approximately 45 NSCLC patients with a KRAS mutation. Its pipeline also includes IPI-145, an inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase I development to treat in flammation and hematologic malignancies. Infinity Pharmaceuticals has a strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited to develop and commercialize pharmaceutical products; and a development and license agreement with Millennium to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K, including IPI-145. Purdue Pharmaceutical Products is planning to conduct Phase II studies of IPI-940 in pain. The company is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Keith Speights]

  No win for the spin
  Another biotech, Infinity Pharmaceuticals (NASDAQ: INFI  ) , also announced clinical results this week. The company's press release trumpeted "encouraging" findings for its experimental leukemia drug. Mr. Market didn't appear to buy the spin. Infinity shares tanked nearly 33% for the week.

• [By Bryan Murphy]

  When investors think of non-Hodgkin's lymphoma stocks, big names like Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) come to mind. Both GILD and CELG are making prolific progress in the war on NHL, and both are fine, well-positioned companies. It's little Infinity Pharmaceuticals Inc. (NASDAQ:INFI) that may end up making the proverbial quantum leap in the non-Hodgkin's lymphoma stocks arena, however, and better still, it's INFI shares that may well end up doling out a much bigger reward than Gilead or Celgene could to newcomers.

• [By Ben Levisohn]

  Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.